-
Although the invasive Burmese pythons might be considered one of the state's most reviled reptiles, they have the potential to help with medical research. Stephen Hall tells us more on "The Florida Roundup."
-
Access remains limited to these effective but expensive drugs, even for patients covered by Medicaid, because of stringent prerequisites that must be satisfied before starting the drug.
-
Participants who took tirzepatide (Zepbound) dropped an average of 50 pounds over 72 weeks. Those who took semaglutide (Wegovy), lost about 33 pounds.
-
Recent research from Drexel University explores a diet intervention specifically aimed at tackling the uniquely addictive nature of your standard gas station snack.
-
The drugmaker said it would stop studying danuglipron after a participant in one of its trials experienced a possible drug-induced liver injury that ended once the person stopped the treatment.
-
Experts tend to focus on the kinds of foods you can eat to improve your health. But the speed at which you devour your dinner matters just as much.
-
Many employers and insurers are scaling back coverage and Medicare doesn’t cover the drugs for obesity. Meantime, some big employers are adding coverage, but their commitment isn’t guaranteed.
-
A new study finds that three quarters of American adults and half of adolescents are too heavy. That's making more of us sick and creating enormous health care costs.
-
Some Trump insiders are ready to take on the food industry. It remains to be seen whether their entree will result in any meaningful change in government oversight of “Big Food” — or in American health.
-
Will you still carry this added weight on New Year's Day 2026? For a quarter of us, that is probably going to prove true, according to a survey.